VCG
BSX icon

Vantage Consulting Group’s Boston Scientific BSX Stock Holding History

Vantage Consulting Group’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,778
Closed -$64K – 319
2020
Q4 		$64K Buy
+1,778
New +$64.1K 0.01% 359

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Vantage Consulting Group's BSX Position: Q1 2021 in Review

Vantage Consulting Group sold out of Boston Scientific (BSX) in Q1 2021, closing a stake of 1,778 shares — an estimated $64K sold.

Vantage Consulting Group first reported a position in BSX in Q4 2020 and held it in 1 quarter. The position peaked at $64K in Q4 2020. 830 funds tracked by Wall St. Rank hold BSX as of Q1 2021.

  • Vantage Consulting Group reported no remaining Boston Scientific position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 1,778 Boston Scientific shares in Q1 2021, an estimated $64K.
  • Vantage Consulting Group first reported a position in Boston Scientific in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Boston Scientific position peaked at $64K in Q4 2020.
  • 830 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.